GeoVax Labs is a clinical-stage biotechnology company developing novel therapies and vaccines for cancers and many of the world’s most threatening infectious diseases. The company’s lead program in oncology is a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, presently in a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax’s lead infectious disease program includes GEO-CM04S1, a next-generation Covid-19 vaccine designed for the growing population of high-risk immunocompromised patients with cancers, autoimmune conditions, and neuromuscular diseases. Currently in two Phase 2 clinical trials, CM04S1 is being evaluated as a Covid-19 vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized Covid-19 vaccines are insufficient. In addition, CM04S1 is in a Phase 2 clinical trial evaluating the vaccine as a more robust, durable Covid-19 booster among healthy patients who previously received the mRNA vaccines. A synergistic program is underway with the rights from the US NIH to make GeoVax the first U.S. supplier of the vaccine vector MVA for protection against Monkeypox and Smallpox. GEO-CM04S1 GeoVax has a solid financial foundation, is listed on Nasdaq (“GOVX”), with a leadership team who have driven significant value creation across multiple life science companies over the past several decades.